SSTR2 expression in ≥ 50% of tumor cells was associated with worse RFS with an estimated 5-year RFS of 11.4% (95% CI: 0%-32.5%) vs 72.7% (95% CI: 46.4%-99.0%) in patients with 1-49% of tumor cells expressing SSTR2 (p=0.007). Here, SSTR2 is linked to neoplasm.